PhaseⅡClinical Trial of Dasatinib for Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase and Stop Therapy After Achieving Complete Molecular Response for Cure D-NewS
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The overall probability of maintenance of complete molecular remission after stopping dasatinib as measured by RQ-PCR
by 12 months
No
Japan: Ministry of Health, Labor and Welfare
KCSG-04
NCT01887561
November 2012
Name | Location |
---|